bpc 157 austin Peptide Therapy Home Page | Ways2Well

Results vary depending on: Some people report gradual improvements over several weeks, while others may require longer treatment periods

LY3437943 (Retatrutide): discovery to clinical proof of concept (triple GLP-1/GIP/glucagon agonist, preclinical mechanism) Nature Reviews Endocrinology (2024) Multi-receptor agonists for metabolic disease (mechanism of GLP-1/GIP/glucagon co-activation) Diabetes Care (2024) Incretin-based therapies: GLP-1, GIP, and glucagon receptor pharmacology (metabolic pathways, energy expenditure) NEJM (2023) Supplementary Material Jastreboff et al

Can oxidise, hydroxylate, or otherwise modify the compound's structure

None of this means the peptides are worthless or that future trials won't show benefit